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Amyotrophic lateral sclerosis (ALS) is a largely sporadic progressive neurodegenerative
disease affecting upper and lower motoneurons (MNs) whose specific etiology is
incompletely understood. Mutations in superoxide dismutase-1 (SOD1), TAR DNA-
binding protein 43 (TARDBP/TDP-43) and C9orf72, have been identified in subsets of
familial and sporadic patients. Key associated molecular and neuropathological features
include ubiquitinated TDP-43 inclusions, stress granules, aggregated dipeptide proteins
from mutant C9orf72 transcripts, altered mitochondrial ultrastructure, dysregulated
calcium homeostasis, oxidative and endoplasmic reticulum (ER) stress, and an unfolded
protein response (UPR). Such impairments have been documented in ALS animal
models; however, whether these mechanisms are initiating factors or later consequential
events leading to MN vulnerability in ALS patients is debatable. Human induced
pluripotent stem cells (iPSCs) are a valuable tool that could resolve this “chicken or
egg” causality dilemma. Relevant systems for probing pathophysiologically affected cells
from large numbers of ALS patients and discovering phenotypic disease signatures
of early MN susceptibility are described. Performing unbiased ‘OMICS and high-
throughput screening in relevant neural cells from a cohort of ALS patient iPSCs, and
rescuing mitochondrial and ER stress impairments, can identify targeted therapeutics for
increasing MN longevity in ALS.
Keywords: ALS, motoneurons, C9orf72, TDP43, mitochondria, endoplasmic reticulum, calcium homeostasis,
iPSCs
INTRODUCTION
Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, is one of the most common
neurodegenerative disorders and adult-onset motoneuron disease (MND), with a global
incidence of 2.5 cases per 100,000 individuals each year, and is classified as a rare disease.
The disease is primarily characterized by a relentless degeneration of upper motoneurons
(UMNs) in the cerebral cortex and lower motoneurons (LMNs) in the brain stem and spinal cord,
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causes muscle weakness, progressive paralysis, speech and
swallowing disabilities, and ultimately leads to death by
respiratory failure (Al-Chalabi and Hardiman, 2013). A definite
cause for ALS is not known except for a minority of cases with
a familial history pointing to a genetic mutation as an origin
(Table 1). ALS exists in two forms: heritable (familial, fALS) and
idiopathic (sporadic, sALS), with the former featuring autosomal
dominant or recessive inheritance patterns in 10% of total ALS
cases and the latter represent the overwhelming majority of ALS
cases (Cozzolino and Carri, 2012).
Since the discovery of the first gene responsible for familial
forms of ALS, superoxide dismutase-1 (SOD1), fundamental
advances in our understanding of the disease have been
made with regard to biological, genetic and clinical processes
(Cozzolino and Carri, 2012). Currently, ALS is considered
a multi-factorial syndrome with motor system degeneration
only being part of a more widespread disease process (Ilieva
et al., 2009). Although, it is still not understood why particular
populations of neurons are particularly vulnerable, increasing
evidence over recent years emphasized that in addition to MNs,
other cell types such as astrocytes, microglia, oligodendrocytes
(OGs) and muscle cells may also actively participate in disease
processes, such as neuroinflammation and muscle degeneration
(Robberecht and Philips, 2013).
An ever-growing number of genes have been identified that
are associated with ALS pathogenesis and account for a large
fraction of familial cases of the disease, even in sporadic forms
(Table 1). Interestingly, many of the same genetic mutations
reported to be involved in familial and some sporadic forms
of ALS have also been found to be associated with non-
MN phenotypes, such as dementia in frontotemporal lobar
degeneration (FTLD; Cooper-Knock et al., 2014), emphasizing
a great overlap in the molecular pathogenesis of both disease
entities (Goldstein and Abrahams, 2013).
In recent years the major focus of ALS research has moved
to RNA related control of MN function and pathogenesis.
Mutations in transactive response (TAR) DNA-binding
protein (TARDBP or TDP43; Kabashi et al., 2008) and fused
in sarcoma/translocated in liposarcoma (FUS/TLS, ALS6;
Kwiatkowski et al., 2009; Vance et al., 2009) have been linked
to fALS. The two proteins are involved in the regulation of
RNA transcription, splicing, transport and translation and this
enabled the establishment of new experimental models, both,
in vivo and in vitro (Sreedharan et al., 2008; Vance et al., 2009;
TABLE 1 | Gene mutations in clinical ALS.
Clinical subtype Locus Gene Onset/inheritance Phenotype
Removal of reactive oxygen species
ALS1 21q22 Superoxide dismutase-1 (SOD1) Adult/AD Classical
RNA binding and processing
ALS4 9q34 Senataxin (SETX ) Juvenile/AD Classical
ALS6 16p11.2 Fused in sarcoma (FUS) Adult/AD Classical
ALS9 14q11.2 Angiogenin (ANG) Adult/AD Classical
ALS10 1p36.2 TAR DNA-binding protein 43 (TARDBP) Adult/AD Classical
ALS13 12q24.12 ATXN2 Adult Classical
Endosomal trafficking and cell signaling
ALS2 2q33 Alsin (ALS2) Juvenile/AR Classical
ALS11 6q21 Polyphosphoinositide phosphatase (Figure 4) Adult/AD
ALS8 20q13.3 Vesicle-associated membrane protein-associated protein B (VAP-B) Adult/AD Classical
ALS12 10p13 Optineurin (OPTN) Adult/AD and AR Atypical
ALS–FTD 9q21–q22 Chromosome 9 open reading frame 72 (C9ORF72) Adult/AD Atypical
Glutamate excitotoxicity
ND 12q24 d-amino acid oxidase (DAO) Adult/AD Atypical
Ubiquitin/protein degradation
ND 9p13–p12 Valosin-containing protein (VCP) Adult/AD Atypical
ALSX Xp11 Ubiquilin 2 (UBQLN2) Adult/X-linked Classical
Cytoskeleton
ALS–dementia–PD 17q21 Microtubule-associated protein tau (MAPT ) Adult/AD Atypical
Other processes
ALS5 15q15–q21 Spatacsin (SPG11) Juvenile/AR Classical
ALS–FTD 9p13.3 σ Non-opioid receptor 1 (SIGMAR1) Adult/ADJuvenile/AR Atypical
Unknown processes
ALS3 18q21 Unknown Adult/AD Classical
ALS7 20ptel–p13 Unknown Adult/AD Classical
A list of genes associated with classical and atypical ALS. The left column groups the genes according to their cellular functions, the second to left column lists the
corresponding chromosomal locus, and the middle column gives the gene name, if applicable. In the second to right column the time of disease onset and means
of inheritance are displayed, while the right column links each gene to the disease phenotype in the clinic. AD, autosomal dominant; AR, autosomal recessive; FTD,
frontotemporal dementia; PD, Parkinson’s disease.
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Zhou et al., 2010a). A more recently identified gene, C9orf72, is
profoundly affected by expansions of GGGGCC (G4C2) repeats.
C9orf72 encodes for a protein with two different isoforms: (i) a
mainly diffuse in the cytoplasm localized C9-L and (ii) a nuclear
membrane localized C9-S (Xiao et al., 2015). The latter one
shows redistribution to the cytoplasm of diseased MNs in ALS
and an interaction with the nuclear pore complex components
importin β1 and Ran-GTPase. The finding of reduced levels of at
least one C9orf72 transcript in expanded-repeat-carriers suggests
a potential loss-of-function mechanism (Dejesus-Hernandez
et al., 2011; Renton et al., 2011; Gijselinck et al., 2012; Donnelly
et al., 2013; Sareen et al., 2013). Alternatively, the accumulation
of transcripts containing the G4C2 transcripts as nuclear RNA
foci are considered to confer the mutant gene with a toxic
feature via an RNA-dependent gain of function mechanism
(Dejesus-Hernandez et al., 2011; Achsel et al., 2013).
These three genes alone account for more than half of the
reported fALS cases making RNA dys-metabolism one of the
central issues of ALS pathogenesis. Several additional genes have
been found to cause rare or atypical forms of fALS (Table 1).
Nevertheless, based on their biological role and acquired
cellular phenotypes, mutations in these genes have been also
linked to oxidative stress, protein-misfolding and aggregation,
endoplasmic reticulum (ER) and cytoskeleton alterations,
ubiquitin proteasome pathway malfunctions, glutamate-
mediated excitotoxicity, calcium (Ca2+) imbalance, and axonal
transport defects (Cozzolino et al., 2012). Intriguingly, whether
and how these recently described nuclear pore-mediated and
RNA dysmetabolism-related pathways are intricately linked to
oxidative stress pathways and mitochondrial damage phenotypes
observed in many of ALS experimental models should be a focus
of further studies.
Mitochondria play a key role in cellular respiration by
converting nutrients into ATP thereby providing cellular
processes with energy. They are also the main source of
reactive oxygen species (ROS) and act as gatekeepers in
intrinsic apoptotic pathways. Mitochondrial dysfunction can
lead to oxidative stress, failure of cellular bioenergetics and
ultimately to cell death (Figure 1). Thus, an alteration of their
properties could confer an intrinsic susceptibility to stress and
aging of long-lived post-mitotic MNs in MNDs (Cozzolino
et al., 2008; Cozzolino and Carri, 2012). ALS patient tissue
and animal models exhibiting mitochondrial alteration and
dysfunction have frequently been found to also exert ER stress.
As the cellular compartment where secreted and membrane
proteins are synthesized and folded, the ER is equipped with
foldases, chaperones and co-factors to process these proteins
and to prevent misfolding or aggregation. Stress conditions
can interfere with ER function and result in abnormal folding
and aggregation of proteins as has been observed in TDP-
43 and FUS/TLS mutations (Andersen and Al-Chalabi, 2011;
Turner et al., 2013) thus provoking a state of ER stress (Boillée
et al., 2006a; Pasinelli and Brown, 2006; Matus et al., 2013;
Figure 2). Given the large size and long neuritis of MNs,
mitochondria and ER dysfunctions significantly interfere with
their normal electrophysiological function as described in the
following chapter.
Despite enormous advances in understanding the pathogenic
events occurring in ALS, only a small fraction of all reported
cases can be linked to genetic causes (Table 2). Thus the cause
of sALS is largely unknown, and while environmental parameters
have been a subject of many epidemiological studies (Seelen et al.,
2014; Ingre et al., 2015; Malek et al., 2015), unidentified genetic
factors are also thought to be a contributing factor towards
susceptibility of MN degeneration. Considerable efforts have
been made to unravel the genetic etiology of ALS with genome-
wide association studies and other next-generation sequencing
approaches (Renton et al., 2014; Cady et al., 2015). Whole exome
sequencing studies, for instance, have identified de novo risk
genes and pathways, i.e., TBK1 (Cirulli et al., 2015), thereby
shedding new light on established ALS associated genemutations
and how they converge in pathways in fALS and sALS.
In this review, we will outline the main factors that have
been associated with ALS disease progression and pathology,
the impact of organelle dysfunction underlying dysfunction in
MNDs. Mitochondrial dysfunction and ER stress have been
implicated as major events in MN degeneration and we will
highlight findings from animal and cell-based models and
how those contribute to degenerative phenotypes of neuronal
and non-neuronal cells. With an increasing number of studies
utilizing patient-derived induced pluripotent stem cells (iPSCs)
to recapitulate disease phenotypes we will outline some of the
observed phenotypes and to what extent they resemble hallmarks
of disease progression observed in the clinic.
MOTONEURONS INVOLVED IN ALS
The risk of developing ALS peaks between 50–75 years of
age, which is in contrast to other neurodegenerative diseases
such as Parkinson’s disease (PD) or Alzheimer’s disease (AD),
thus emphasizing that it is not necessarily a disease of
aging, but that age is one of the chief risk factors. In a
majority of patients, ALS manifests as asymmetric, painless
weakness in a limb, referred to as spinal onset. About 20% of
patients present with symptoms of weakness in bulbar muscles,
difficulties swallowing (dysphagia) and speech impairment,
referred to as bulbar onset. In about 3–5% of patients, ALS
is characterized by onset affecting the respiratory system, with
shortness of breath and difficulty breathing (orthopnea and
dyspnea). While these symptoms of onset can be overlapping,
the average survival is 2–5 years, with bulbar and respiratory
onsets having a worse prognosis (Swinnen and Robberecht,
2014).
MN diversity is generated during CNS development by
members of the hox gene family and an array of inductive
signaling pathways. Although, it is not yet completely understood
how different subtypes ofMNs are specified during development,
work over the past decades has significantly advanced our
understanding of hox genes conferring regional identity to MN
groups along the rostro-caudal axis (Philippidou and Dasen,
2013). With over 300 bilateral pairs of muscles comprised of
over a 100 million muscle fibers, over 120,000 MNs in the
spinal cord alone account for sensation of muscle, contraction,
respiration and other vital functions. Upper MNs (UMNs) that
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FIGURE 1 | Oxidative stress, protein misfolding and mitochondrial dysfunction are closely related. Excessive production of reactive oxygen or nitrogen
species (ROS/RNS), transcriptional dysregulation, protein misfolding and ER stress can arise as consequences of OS and mitochondrial stress. In addition these
factors work in a feedback-loop further exacerbating mitochondrial stress and dysfunction. A significant amount of mitochondrial proteins, including those of the
ETC, contain highly oxidizable iron-sulfur-clusters that upon exposure to OS can be severely affected in their folding and function. But, OS also triggers stress
responses in other organelles, such as the ER and persistent stress and highly oxidative conditions impair the function and integrity of protein folding in the ER. As a
result the formation of misfolded proteins is favored leading to an accumulation of insoluble cytosolic and mitochondrial aggregates, impaired interference with
activity of the PDI and impaired axonal transport. During the course of these alterations the levels of ATP and intra-cellular calcium are affected. This change
interferes with the Ca2+ and ATP sensitive mitochondrial fusion/fission machinery and microtubule based mechanisms of mitochondrial transport. Mitochondria
accumulate in the cell soma in a fragmented and dysfunctional state leading to a dramatic reduction of mitochondria transported anterograde to the axon terminal.
Given the size of motor neurons with long axonal extensions, the impaired axonal transport leads to a depletion of functional mitochondria at the axon terminal. With
the axonal periphery no longer supplied with sufficient ATP distal synapses degenerate eventually and the MN dies. As a consequence myofibers no longer receive
input from their corresponding MN and are prone to atrophy, manifesting in increased muscle weakness of ALS patients.
are affected in ALS originate either in the motor region of the
cerebral cortex or in the brainstem and carry motor information
down to the lower MNs (LMNs). LMNs are either located in
the anterior gray column and anterior nerve roots—termed
spinal LMNs, or the cranial nerve nuclei of the brain stem
and cranial nerves with motor function, summarized as cranial
nerve MNs. Voluntary movements rely on spinal LMNs, which
innervate skeletal muscle fibers, thereby acting as a link between
UMNs and muscles. In turn, cranial nerve LMNs control
movement of the eyes and tongue as well as contributing to
swallowing, chewing and vocalization (Swinnen and Robberecht,
2014).
Based on the type of muscle LMNs innervate, they can be
further classified into alpha-, beta-, and gammaMNs. AlphaMNs
(αMNs) innervate extrafusal muscle fibers, the most abundant
type of muscle fiber and the type being involved in muscle
contraction. Beta MNs (βMNs) innervate intrafusal fibers of
muscle spindles with collateral extensions to extrafusal slow
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FIGURE 2 | Protein misfolding triggers ER stress in neurons. Misfolded proteins trigger the unfolded protein response (UPR) of the ER, leading to cellular efforts
in either refolding proteins to a normal state or ubiquitinating or degrading unrepairable proteins. Some proteins, i.e., TDP-43 or FUS escape degradation via
proteasomes and autophagy resulting in large aggregates. Also, mutant TDP-43 and FUS accumulate in the cytoplasm. Continuous activation of UPR and other ER
stress responses lead to ER dysfunction, fragmentation of the Golgi apparatus and protein trafficking defects. Adding to this, ROS and RNS released by ER and
mitochondria, as well as excitotoxicity via glutamatergic synapses yield mitochondrial stress and fragmentation and further contribute to ER stress. As a result further
formation of misfolded proteins is favored leading to an accumulation of insoluble cytosolic and mitochondrial aggregates, and an impaired activity of the PDI of the
ER. Collectively, these events culminate with further overall neuronal dysfunction including dynein based transport inhibition. Ultimately, this results in a breakdown of
energy supply for the distal axon terminal. Astroglial dysfunction or toxicity can contribute to MN degeneration as well, whether as initiating event or contributing
factor remains to be determined. Activated astrocytes and microglia can trigger inflammatory responses resulting in further MN stress. Finally, a prion-like hypothesis
posits that misfolded protein aggregates can spread from surrounding cells, either affected dying neurons or astrocytes, and infects MNs thereby initiating stress
responses and ultimately apoptosis in the infected cells.
twitch fibers. Gamma MNs (γMNs) innervate intrafusal muscle
fibers and together with sensory afferents, compose a muscle
spindle and are part of proprioception, the sensing of body
positioning. According to the contractile properties of the
motor units (MU) they form with their target muscles, αMNs
can be further classified into fast-twitch fatigable (FF), fast-
twitch fatigue-resistant (FR) and slow-twitch fatigue-resistant
(SR; Burke et al., 1973).
Subtypes of MNs are Differently Affected in
ALS
Not all MN subtypes are affected equally in ALS. In SOD1
transgenic mice the FF MU undergo atrophy the earliest, with
a nearly total loss of FF terminals from muscle fibers in the
triceps area (Frey et al., 2000). The almost synchronous dieback
is followed by delayed, but likewise rapid fallout of the FR
units, while S MU remain well preserved until late in disease
progression (Pun et al., 2006). Electrophysiological studies and
fiber type analysis confirm the overall sequence of degeneration;
however, they also suggest an initial switch in MU phenotype
from FF to FR to precede the loss of FF axons (Kieran et al.,
2005; Hegedus et al., 2008; Gordon et al., 2010). The relative
resistance observed in FR and S MU may by explained be their
high sprouting capacity, which could enable them to innervate
motor endplates that have been vacated by FF axons (Frey et al.,
2000). In accordance with this electromyogram (EMG) patterns
reflect cycles of denervation/reinervation (de Carvalho et al.,
2008) and the FF MU being affected first in sALS patients as well
(Dengler et al., 1990).
A selective vulnerability of particular neuronal subsets to
the neurodegenerative process is a key feature, not only of
ALS, but of other neurodegenerative diseases. Why certain
subtypes of MNs are particularly susceptible to injury in the
presence of mutations affecting ubiquitously distributed proteins
such as TDP-43 and SOD1, is not well understood. The cell-
specific features of LMNs, i.e., a large cell size, long axons
and large terminal arbors, have great implications for their
energy metabolism, the requirement of mitochondrial and
cytoskeletal support, and the distribution of mRNA for protein
synthesis (Ferraiuolo et al., 2011). LMNs vulnerable to injury in
ALS exhibit particular sensitivity to glutamatergic toxicity via
a-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)
receptor activation. Unlike other neuron groups, they exert
high expression levels of calcium-permeable AMPA receptors
that lack the GluR2 subunit (Williams et al., 1997) and have
Frontiers in Cellular Neuroscience | www.frontiersin.org 5 November 2015 | Volume 9 | Article 448
Kaus and Sareen Disease Signatures in ALS iPSCs
TABLE 2 | Animal models of ALS.
ALS sub-type Gene mutations Animal models
Spontaneous motor neuron degeneration Wobbler Mouse—closely resembles hallmarks of clinical ALS, underlying mutation in
Vps54 not identified in human ALS (Moser et al., 2013)
Neuromuscular degeneration Mouse—Strong neuromuscular degeneration phenotype, underlying mutation in
Ighmbp2 was found in SMA patients (Van Den Bosch, 2011)
Progressive Motor Neuronopathy Mouse—Hindlimb paralysis and progressive motor axon degeneration,
underlying gene product Tbce associated with human hypoparathyroidism
retardation dysmorphism (HRD) syndrome (Van Den Bosch, 2011)
Mendelian fALS SOD1 Mouse/Rat—Strong ALS-like phenotype in G93A, G37R, G85R, and D90A;
variable severity across entity of SOD lines; H4R and G93A do not exert classical
ALS; no TDP-43 abnormalities observed in many lines (Carri et al., 2015)
Worm—Some of the cellular and molecular hallmarks of clinical ALS phenotypes
(Therrien and Parker, 2014)
FUS Mouse/Rat—Some features of clinical ALS (Deng et al., 2014)
Fly—recapitulates key features of ALS (Casci and Pandey, 2015)
Worm—displays molecular MN degeneration phenotypes resembling ALS/FTLD
(Therrien and Parker, 2014)
TDP-43 Mouse/Rat—represents some features of clinical ALS, wide range of phenotype
variation (some lines no MN phenotype), no clear aggregation or loss of nuclear
TDP-43 (Chen-Plotkin et al., 2010; Tsao et al., 2012)
Zebrafish—recapitulates some hallmarks of ALS, strong MN degeneration,
cytoplasmic TDP-43
Fly—recapitulates some ALS aspects, strong MN degeneration documented,
cytoplasmic TDP-43 (Casci and Pandey, 2015)
Worm—MN degeneration phenotype (Therrien and Parker, 2014)
Atypical and rare mendelian ALS ALS2/Alsin Mouse—A very mild, considerably subtle phenotype; no major MN deficits; loss
of cerebellar Purkinje cells (Cai et al., 2005)
VAP-B Mouse—VAP-B (P56S) mutants do not show signs of MN degeneration;
cytoplasmic TDP-43 accumulations in MN and spinal cord (Van Den Bosch,
2011)
Dynactin P150glued Mouse—Axonal transport defects; accumulation of cytoskeletal and synaptic
vesicle proteins at NMJ, loss of spinal motor neurons, increase of astrogliosis
(Van Den Bosch, 2011)
Genetic abnormality in fALS and sALS C9ORF72 Mouse—Motor deficits and loss of cortical and cerebellar neurons similar
to clinical symptoms of ALS/FLTD; RNA-foci, TDP-43 pathology; astrogliosis
(Rohrer et al., 2015)
Zebrafish, fly and worm—MN degeneration, more detailed studies awaiting
(Therrien and Parker, 2014; Casci and Pandey, 2015)
A representation of some of the vertebrate and invertebrate models utilized to study the cellular pathology of MND. The left column group’s spontaneous mutations in
animal models found to closely resemble MND pathology, Mendelian and atypical forms of ALS associated mutations. In the middle column disease associated genes are
listed. The right column summarizes how far ALS-associated phenotypes resemble the designated models.
fairly low amounts of cytosolic calcium-buffering proteins (Ince
et al., 1993). In addition these MNs have a high threshold
for initiating a protective heat-shock protein response, an
increased sensitivity to ER stress (Saxena et al., 2009) and
mitochondrial features that predispose them to calcium overload
and oxidative damage (Sullivan et al., 2004; Panov et al.,
2011).
Data obtained in ALS patients and animal models alike
initially suggested an early axonal dieback and selective
susceptibility of FF axons to occur during human disease
progression (Fischer and Glass, 2007). With a selective dieback
of FF MU in ALS, intrinsic molecular mechanisms conferring
susceptibility to these units lie at hand. In case of the many
different point mutations reported for mutant SOD1, research
has mainly focused on how misfolded SOD1 toxicity impacts the
cell. For instance excessive accumulation of misfolded proteins
leads to stress responses in the ER in an effort to restore cellular
homeostasis. When this process is not successful, as is the case in
SOD1 mutants, ER pathways can trigger apoptosis (Matus et al.,
2013). Interestingly, a recent study targeting mSOD1 in UMN via
an AAV9-shRNA in a presymptomatic SOD1 (G93a) rat model
reported significant delay of disease onset and improved survival
of spinal MNs (Thomsen et al., 2014). These findings suggest
differential vulnerability of MN subtypes alongside early UMN
dysfunction during the presymptomatic phase of disease course.
With the recognition of non-neuronal cells such as glia
and activated microglia also have a major contribution to the
progression and outcome of the disease three scenarios have been
hypothesized: (I) The ‘‘dying forward’’ hypothesis suggests that
events within the MN are the primary determinant initiating
MN damage, while alterations in closely associated non-neuronal
astrocytes, Schwan cells, microglia and skeletal muscle cells only
contribute to the disease progression; (II) In a counter-proposed
‘‘dying backward’’ mechanism, ALS is considered to begin within
the muscle cells and/or neuromuscular junction as a result of one
ormore neurotrophic factors being released by postsynaptic cells.
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When retrogradely transported via the presynaptic axon to the
cell body those factors may initiate MN damage and degradation
(Dupuis and Loeffler, 2009); and (III) Alternatively, the ‘‘prion-
like propagation’’ scenario could explain the focal onset and
propagation of misfolded ALS protein seeds via the neuronal
network or the extracellularmatrix (Polymenidou and Cleveland,
2011).
CONTRIBUTION OF OTHER CELL TYPES
TO ALS
GABA-Ergic Interneurons
During the last 20 years, structural and functional neuroimaging
studies have greatly revised our longstanding notions of the
pathophysiology of ALS. In fact, anatomical lesions extend
beyond precentral cortices and corticospinal tracts, and include
the corpus callosum, the frontal, sensory and premotor cortices,
thalamus and midbrain. Theories of glutamate excitotoxicity and
hyperexcitability in ALS suggest the contribution of excessive
synaptic excitation, for instance through AMPA receptors (Kwak
et al., 2010) and Na+ channels. Disease-specific changes in
RNA editing of the AMPA glutamate receptor subunit 2
(GluR2), for instance, have been found in spinal MNs of
human sALS autopsy cases (Kawahara et al., 2004). Clinical
data, however, suggest the possibility of insufficient synaptic
inhibition. Magnetic resonance imaging (MRI) and positron
emission tomography (PET) studies in patients revealed an
early and diffuse loss of inhibitory cortical interneurons and
diffuse gliosis in white matter tracts (Chió et al., 2014).
In fact, MN excitability is strongly modulated by synaptic
inhibition mediated by presynaptic glycinergic and GABAergic
innervations and postsynaptic glycine receptors (GlyR) and
GABAA receptors (Martin and Chang, 2012).
Abnormal glycine and GABA levels have been observed in
ALS patients (Malessa et al., 1991; Niebroj-Dobosz and Janik,
1999; Eisen and Weber, 2000). In human ALS autopsy samples
of the spinal cord, glycine binding sites are reduced in the
anterior horn and in human ALS autopsy motor cortex (Hayashi
et al., 1981; Whitehouse et al., 1983). In agreement with this,
mRNA levels of the alpha1-subunit of the GABA receptor of
inhibitory interneurons was significantly reduced, while the
GABA synthesizing enzyme glutamic acid decarboxylase (GAD),
in turn, was dramatically upregulated in the prefrontal and
temporal cortices of ALS patients (Petri et al., 2006). In the
spinal cord of adult transgenic G93A-hSOD1 transgenic mice
(Schutz, 2005), as well as organotypic spinal cord-slice cultures
of embryonic G93A-hSOD1 transgenic mice (Avossa et al.,
2006), signs of imbalance excitatory and inhibitory innervations,
indicative of aberrant neuroplasticity, are evident. Thus aberrant
or even failed inhibition may be involved in ALS mechanisms of
disease.
Glia—Microglia
The immune system plays a crucial role in the maintenance
of tissue homeostasis and the response to injury or infection.
Within the central nervous system (CNS) microglia, the major
resident immune cells, constantly survey the microenvironment
and produce factors that influence other glial cells such as
astrocytes. While microglia remain in a deactivated state
during physiological conditions (Streit, 2002) they switch to
an activated state upon pathogen invasion or tissue damage
detected by their Toll-like receptor 4 (TLR4) and promote
inflammatory responses via mediators such as TNF-α or IL-
1β, engaging the immune response and tissue repair (Saijo
et al., 2009). Usually this response is self-limiting and is
resolved when infection has been eradicated or tissue damage
has been repaired. Sustained inflammation, however, leading
to tissue damage implies persistent inflammatory stimuli or
failure in resolution mechanisms. A persistent stimulus can
either result from environmental factors or chronic persistence
of endogenous factors, being perceived by the immune system as
‘‘stranger’’ or ‘‘danger’’ signals and the subsequent inflammatory
responsesmay overwhelm normal resolutionmechanisms.While
some inflammatory stimuli produce beneficial effects, i.e.,
phagocytosis, uncontrolled inflammation may as well result in
generation of neurotoxic factors that amplify the underlying
disease states (Glass et al., 2010).
Signs of neuroinflammation can be readily observed in
pathologically affected areas in the brain and spinal cord in
both human ALS patients as well as mouse models of the
disease. Characteristic for ALS are gliosis and accumulation of
large numbers of activated microglia and astrocytes marked
by elevated production of inflammatory mediators (i.e., COX-
2), proinflammatory cytokines (i.e., IL-1β, IL-6 and TNF-α)
and potentially cytotoxic molecules such as ROS. For instance,
major histocompatibility complex molecules and complement
receptors were found highly expressed by activated microglia in
the primarymotor cortex and the anterior horn of the spinal cord
in ALS patients (McGeer and McGeer, 2002). Receptors of the
innate immune response could be potential sensors of molecules
that induce or amplify inflammation in ALS (Letiembre et al.,
2009), given that CD14, a protein facilitating TLR4 responses
to lipopolyssaccharides (LPS), and TLR2 are upregulated in
the spinal cords of mouse models (Nadeau and Rivest, 2000;
Nguyen et al., 2001) and ALS patients (Letiembre et al., 2009;
Liu et al., 2009). Indeed, a study conducting chronic infusion of
presymptomatic ALS mice with LPS documented an enhanced
innate immune response and exacerbated disease progression
(Nguyen et al., 2004). Another piece of evidence for an active
involvement of microglia in disease progression is the finding
that mutant SOD1, but not wild-type protein, is presumably
secreted into the extracellular space via chromogranin vesicles,
resulting in activation of microglia and MN death in culture
(Urushitani et al., 2006). Consistent with this is the toxicity of
ALS patient derived CSF for exposed rat spinal cord cultures and
the presence of mSOD1 within this CSF (Tikka et al., 2002) and
intracerebral infusion of mutant SOD1 into wild-type mice can
induce microglia activation and cytokine production (Kang and
Rivest, 2007).
Glia—Astrocytes
Even though MNs are the primary cells affected in ALS,
accumulating evidence points to a role of supporting astroglia
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during pathogenesis. MNs isolated from transgenic mSOD1
mice were found to be more sensitive to Fas or NO triggered
cell death than in wild-type neurons suggesting a MN specific
death pathway (Raoul et al., 2002). Binding of the ligand
FasL to the Fas receptor leads to its intracellular portion
recruiting the adaptor protein FADD which in turn activates
a caspase cascade that culminates ultimately in MN death.
While this pathway was found activated in presymptomatic
ALS mice as well (Raoul et al., 2006), it is noteworthy that
mSOD1 astroglia produce significant NO and FasL (Barbeito
et al., 2004), thus implying that astroglia could in fact be the
executioner of MN death in ALS. In line with this, the p75
neurotrophin receptor (p75NTR) has been associated with ALS-
associated MN death, as nerve growth factor (NGF) secreted
by mSOD1 astrocytes induced death of p75NTR expressing
MNs via the formation of NO and peroxide (Pehar et al.,
2004).
Cell-specific targeting of mSOD1 deletion in astrocytes
and microglia utilizing GFAP-cre and CD11b-cre transgenes,
respectively, was found to reduce severity of the disease
phenotype and dramatically improve survival of ALS mice
(Boillée et al., 2006b; Yamanaka et al., 2008b). While concerns
related to the timing and efficiency of gene targeting in
these mice have been raised, additional supporting evidence
for an involvement of non-neuronal cells comes from studies
with chimeric mice selectively expressing mSOD1 in MNs
and non-neuronal cells. In such chimeras the presence of
wild type non-motor neurons significantly delayed the onset
of MND despite a high penetrance of mSOD1 MNs and
OGs, increasing disease free life by 50% (Yamanaka et al.,
2008a), and in co-cultures mSOD1 astrocytes exerted toxic
effects on healthy wild-type MNs (Di Giorgio et al., 2008;
Marchetto et al., 2008). These experiments suggest a non-
cell-autonomous scenario, for SOD1-meidated ALS at least, in
which sick or mutant astrocytes directly contribute to MN
degeneration.
That non-neuronal cells have a crucial impact on MN
degeneration is also supported by the finding of mutant protein
aggregates in neighboring astrocytes (Zhang et al., 2008).
In a series of elegant experiments dramatic impact of ALS
associated TDP-43 mutations were evident in human astrocytes.
The authors generated a significantly purified population of
astrocytes from patient-derived iPSCs with specific TDP-
43 mutations (M337V) characterizing the cellular phenotype
and found the astrocyte cultures to accumulate 30% more
cytoplasmic TDP-43 than control astrocytes. Control-astrocytes
that were transfected with mutant TDP-43 in turn displayed
a similar amount of cytoplasmic TDP-43 accumulation (Serio
et al., 2013). This emphasizes a direct responsibility of the specific
TDP-43 mutation in the observed subcellular mislocalization.
Glia—Oligodendrocytes
OGs are of particular importance for neuronal function and
axonal transmission as they insulate axons with an essential
myelin sheath. This myelin sheath allows for the fast and
efficient propagation of action potentials and neuronal electrical
transmission over long distances through saltatory conduction
(Nave, 2010a,b; Simons and Lyons, 2013). Apart from this,
OGs are a principal supplier of metabolic energy to axons and
neurons.
Until recently, the involvement of OGs and their precursors
in the pathogenesis of ALS was fairly unexplored. Abnormalities
of OGs, such as pathological inclusions immunoreactive for
smooth muscle alpha-actin, but neither angiotensin nor TDP-43,
were observed in affected post mortem tissue of ALS patients.
Pathological aggregates sequestering the ALS-linked protein
TDP-43 occur in the cytoplasm of OGs from both sporadic
and familiar ALS patients (Seilhean et al., 2009; Murray et al.,
2011; Philips et al., 2013). Another ALS-linked protein, FUS, was
found sequestered into cytoplasmic inclusion of patients with
FUS-linked ALS. Interestingly, patients with late onset of FUS-
linked ALS are characterized by highly abundant FUS inclusions
in OGs, while early onset patients preferentially have neuronal
cytoplasmic inclusions (Mackenzie et al., 2011; Nonneman et al.,
2014).
Studies on ALS-linked mSOD1 transgenic mice revealed that
gray matter OGs in the spinal cord degenerate before the first
symptoms of MN degeneration become apparent (Kang et al.,
2013; Philips et al., 2013). Indicatory for this OG degeneration
is an abnormal morphology manifested in thickened, irregularly
shaped cell body, enlarged cytoplasm and elongated reactive
processes. Such dysmorphic OGs are in an apoptotic state
characterized by cleaved caspase-3 immunoreactivity and altered
chromatin condensation (Kang et al., 2013; Philips et al.,
2013) and are significantly increased in SODG93a mice already
before disease onset and are progressively increasing throughout
(Philips et al., 2013). In addition, dense clustering of reactive
microglia around degenerating OGs can be observed (Kang
et al., 2013). Lineage tracing of OGs with a tamoxifen-
inducible OG-specific Cre line in mSOD transgenic mice (Plp-
CreER; Rosa26-EYFP, SOD1G93A) confirmed the progressive
decrease in the number of OGs as a function of disease
progression in SOD1G93A mice (Kang et al., 2013; Philips
et al., 2013). Morphological examination, however, revealed
dysmorphic somata and branches and altered lipid and protein
composition of the myelin sheath. Besides myelin defects, the
newly generated OGs also fail to supply neurons with metabolic
energy substrates, including lactate, pyruvate and ketone bodies
(Philips et al., 2013). In addition, activated microglia and
astrocytes exert OG toxicity as microglia for instance produce
ROS and secret pro-inflammatory cytokines (Nonneman et al.,
2014).
Although inflammation may not necessarily represent an
initiating factor in neurodegenerative diseases, intriguing
evidence obtained both from patient tissue and from
animal models over the recent years stressed that sustained
inflammatory responses involving microglia, astrocytes and
OGs contribute to disease progression (Figure 3). This is
the case not only in ALS and FTLD but in many other
neurodegenerative diseases such as Alzheimer’s, Parkinson’s and
multiple sclerosis (Glass et al., 2010). Whether inhibition
of sustained inflammatory responses can be a safe and
successful means to reverse or to at least slow down the
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course of disease progression should be a focus of further
investigations. Disease-in-a-dish models utilizing ALS patient
iPSC-derived co-cultures of MNs with astrocytes or OG
could be used to study whether pharmacological inhibition
of inflammation in the latter two cell-types would improve
MN survival in vitro. As a second step such astrocytes and
OG with pharmacological inhibition of inflammation could
be transplanted into the CNS of ALS disease animal models
to evaluate whether reducing inflammation in non-neuronal
cells in vivo would ultimately slow MN degeneration or
even improve MN health. Should this be the case, it will
point to inflammation being the key contributor to trigger
mitochondrial dysfunction, Ca2+-imbalance and ER stress
responses.
MITOCHONDRIAL INVOLVEMENT IN ALS
Mitochondria perform diverse functions, such as producing ATP
via oxidative phosphorylation, and regulating cellular levels of
metabolites, amino acids and co-factors for various regulatory
enzymes. As a main source of ROS and buffer of spatiotemporal
Ca2+ homeostasis, they integrate signals with other cellular
compartments and contribute to cellular stress responses such
as autophagy and apoptosis (Nunnari and Suomalainen, 2012).
Further, mitochondrial fission and fusion specifies health in
metabolic disorders and neurodegenerative diseases (Chen and
Chan, 2009; Westermann, 2010).
The unique cytological properties of MNs, such as
their extended cell size and the large volume of the axonal
compartment, require a high metabolic demand and crucially
depend on a robust cytoskeleton and axonal transport
mechanisms. Due to that, MNs show increased generation
of ROS and a tendency towards oxidative stress, making them
particularly prone to other factors, i.e., ER stress, altered calcium
levels and excitotoxicity (Figure 1). Developmental defects due
to genetic mutations may confer mitochondria with an inert
susceptibility towards developing MND (Ferraiuolo et al., 2011)
as discussed.
Structural Alterations
In samples of ALS patients an altered ultrastructure is evident,
with swollen and vacuolated mitochondria found in MNs,
muscles, and intra-muscular nerves (Afifi et al., 1966; Atsumi,
1981; Siklos et al., 1996; Sasaki et al., 2007). Axonal swellings in
MNs, Bunina bodies, comprised of accumulated neurofilaments,
organelles and secondary lysosomes have been observed in the
remaining LMNs and constitute a hallmark of ALS-specific
histopathology (Hart et al., 1977; Okamoto et al., 1990). Imaging
experiments on MNs derived from ALS transgenic mSOD1 mice
revealed a reduced mobility (Magrane et al., 2009) and a net
increase in retrograde transport of mitochondria away from the
axon terminal, resulting in a depletion (De Vos et al., 2007,
2008).
A common feature of mitochondrial morphology changes
in cellular and animal models of ALS is fragmentation of
the mitochondria. Expression of mSOD1 in neuronal cells
per se induces mitochondrial fragmentation. This pattern
of alteration in mitochondrial morphology is for instance
observed when interfering with the expression of aptic
atrophy 1 (OPA1), a pro-fusion factor, dynamin related
protein 1 (Drp1; Ferri et al., 2010) and other factors such
as PINK1 (Matsuda et al., 2010; Deas et al., 2011). While
mitochondrial alteration has been extensively studied in mSOD1
animal models, it remains to be determined, whether such
changes are consistently found in other ALS associated
mutations, both in animal models and human stem cell
derived MNs.
Reactive Oxygen Species (ROS) and
Oxidative Stress
Mitochondria are particularly vulnerable to oxidative stress given
that: (i) excessive ROS leads to lipid peroxidation interfering
with mitochondrial membrane integrity; (ii) a plethora of
mitochondrial proteins, such as essential proteins of the
ETC complexes, contain highly oxidizable iron-sulfur clusters;
and (iii) due to the lack of protective histone complexes
mitochondrial DNA is far more susceptible to mutations in
organelle encoded proteins (Cozzolino et al., 2012). Thus,
conditions that interfere with mitochondrial homeostasis or
lead to mitochondrial dysfunction are self-sustaining due to
increased ROS production and accumulation. Experimental
evidence obtained in mouse models have the focus of other
reviews (Cozzolino et al., 2012).
Localized oxidative stress in ALS mitochondria, specifically
ETC impairments, has been documented in patients and SOD1
mice (Kong and Xu, 1998; Miana-Mena et al., 2005). This
was accompanied by energy deficits in the spinal cord (Jung
et al., 2002; Mattiazzi et al., 2002; Kirkinezos et al., 2005),
primary astrocytes and primary motor cortex (Cassina et al.,
2008; Loizzo et al., 2010). A reduction in mitochondrial repair
enzymes in patients and SOD1 mice (Kikuchi et al., 2002;
Murakami et al., 2007), and markers of oxidative stress such
as lipid peroxidation, protein glycoxidation and altered protein
carbonyl levels in patient samples (Shibata et al., 2002) emphasize
an exacerbating mitochondrial dysfunction in ALS (Mahoney
et al., 2006). In mSOD1 mice phenotypes manifest in muscles
with hypermetabolism, reduced adipose tissue accumulation and
elevated energy expenditure already in the asymptotic phase
(Dupuis and Loeffler, 2009; Dupuis et al., 2009). Such findings,
however, have not been reported in patients and other ALS
models, raising the question whether the early oxidative stress
associated muscle phenotype in SOD1 animal models is an
ALS specific early phenotype or, instead, rather a sub-form of
ALS, specific to mutations in SOD1, and finally, whether such
phenotypes may only be specific to the SOD1 animal models
themselves.
Calcium Buffering and Homeostasis
MNs express a large number of Ca2+ permeable receptors
lacking the GluR2 subunit (Greig et al., 2000; Heath et al.,
2002; Van Damme et al., 2002; Kawahara et al., 2003), and in
addition to that, have particularly low Ca2+ buffering abilities
(Lips and Keller, 1998; Palecek et al., 1999). This could make
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MNs particularly sensitive to glutamate toxicity exerted through
AMPA receptors, however would mostly contribute to disease
severity in later stages (Grosskreutz et al., 2010; Cozzolino and
Carri, 2012). In turn selective loss of the astroglial glutamate
transporter GLT1 is amore likely scenario of neurotoxicity due to
impaired glutamate clearance from the synaptic cleft (Rothstein
et al., 1995; Bendotti et al., 2001; Howland et al., 2002).
Toxic Ca2+ dysmetabolism in ALS is probably mostly
evoked by a deficiency in intracellular Ca2+ mishandling, as a
consequence of low levels of Ca2+-binding proteins or impaired
mitochondrial Ca2+ buffering. Supporting this, calbindin D-28K
immunoreactivity was found reduced in the frontal cortex of
patients with FTLD (Ferrer et al., 1993), and in ALS patients,
with significant differences in the densities of calbindin positive
neurons within cortical layers V and VI (Maekawa et al.,
2004). A loss of calbindin and parvalbumin immunoreactivity
from subsets of MNs in presymptomatic mSOD1 mice suggests
calbindin loss as an early event in ALS pathogenesis (Sasaki et al.,
2006).
Evidence for defective Ca2+ storage as a result of
mitochondrial dysfunction initially came from cell models
for SOD1-linked ALS, which displayed elevated cytoplasmic
Ca2+ levels in conjunction with compromised mitochondrial
gradient potential (Carri et al., 1997; Jaiswal et al., 2009). In
animal and cell models of mSOD1, MNs expressed markers
of oxidative stress and mitochondrial dysfunction, elevated
Ca2+ levels and vulnerability to glutamate toxicity (Kruman
et al., 1999). Further in vivo studies manifested prolonged
Ca2+-induced membrane polarization in an early decrease in
mitochondrial Ca2+ loading capacity, impaired Ca2+ uptake in
neurons and muscle tissue (Damiano et al., 2006; Jaiswal and
Keller, 2009; Nguyen et al., 2009; Zhou et al., 2010b). Adding
to this it has been found that Ca2+ is able to bind to SOD1
immature states and promote its aggregation (Leal et al., 2013).
This emphasizes that, apart from mutations in ALS-related
proteins disrupting calcium homeostasis, Ca2+ itself affects
ALS-critical proteins and cellular processes as well.
In summary, Ca2+ dysregulation and mitochondrial
pathology are tightly interconnected. Apart from SOD1,
however, many other ALS-critical proteins have been shown
to potentiate Ca2+ dysregulation thereby increasing cellular
Ca2+ vulnerability as well (Leal and Gomes, 2015). Altered
Ca2+-influx can increase ROS production and accumulation
and cytochrome c release, making this process self-sustaining
and steering towards activation of cell death (Dykens, 1994).
Although it is tempting to speculate that Ca2+ could be the one
factor shifting MN integrity out of balance, future studies will
need to address early Ca2+ phenotypes further. Intriguingly,
Ca2+ dysregulation and mitochondrial pathology are also
intimately connected to protein aggregation as we will discuss in
the next chapter.
Non-SOD1 Mutation Derived Mitochondrial
Alteration and Damage
In recent years, a number of studies have described
mitochondrial alteration and dysfunction in non-mutant-
SOD1-linked cases of ALS. TDP-43, a protein with dual
functions as DNA-binding protein with nuclear export sequence
and as RNA-binding protein, is found to be predominantly
localized to the cytosol instead of the nucleus in ALS spinal
MNs, found in punctate immunoreactive granules and as dense
skeins (Kabashi et al., 2008). Transgenic mice overexpressing
a human TDP-43 (hTDP-43) under the control of the mouse
prion protein reporter in the brain and spinal cord, produce an
ALS-like phenotype exhibited by reactive gliogenesis, axonal
and myelin degeneration, gait abnormalities and early lethality.
The hTDP-43 overexpression induces abnormal perinuclear
aggregates of mitochondria accompanied by enhanced levels
of fission and fusion components, Fis1, phosphorylated Dlp1
and mitofusin 1, respectively (Xu et al., 2010). Accumulation
of mitochondria in TDP-43-negative cytoplasmic inclusions
in MNs was also found in a Thy1.2; hTDP-43 mouse model
that notably lacked mitochondria in motor axon terminals.
This, however, could be due to an alteration in elements of
the transport machinery, kinesin-associated proteins Kif3a and
KAP3, found in inclusions (Shan et al., 2010). Alternatively, it
has been observed that TDP-43 stabilizes the RNA of human low
molecular weight neurofilament protein via interaction with the
3′UTR, altering its location in spinal MNs and thereby possible
favoring the formation of NF aggregates in ALS (Strong et al.,
2007) and mitochondria mis-localization.
The RNA-binding protein FUS/TLS is normally localized
in the nucleus where it participates in process involved in
RNA maturation, among those snRNP biogenesis, alternative
splicing, and mRNP localization. Most of the research on the
role of mutant FUS in ALS has focused on its mislocalization
and aggregation, and little is known about its involvement in
mitochondrial dysfunction. Mutant forms of FUS/TLS were
found to accumulate in the cytoplasm, similarly to TDP-43,
and form protein inclusions in spinal horn neurons derived
from ALS patients (Deng et al., 2010). In a few juvenile ALS
cases post-mortem tissue analysis of MNs revealed basophilic
inclusions containing abnormal aggregates of FUS proteins and
disorganized intracellular organelles, among those mitochondria
and endoplasmic reticuli (Huang et al., 2010).
While the SOD1 model may only represent a small fraction of
the heterogeneous disease population and posits a note of caution
when interpreting mSOD1 mouse phenotypes at large across
idiopathic forms of ALS, recent findings supporting the view
of OS and mitochondrial damage to play a role in non-SOD1
ALS also come from cell and invertebrate models (Carri et al.,
2015). The phenotypes found in mutant TDP-43 and FUS/TLS
support the concept of mitochondrial dysfunction and damage
as a major event in ALS progression. Further investigation is
needed to elucidate if mitochondrial alteration and dysfunction
phenotypes in non-SOD mutants occur at early disease stages as
a key gateway in ALS pathogenesis.
Mitochondrial Susceptibility as Cause vs.
Result of ALS
While ALS-associated mutations can to some extent explain
the circumstances leading to ROS and Ca2+ dysregulation in
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MN ultimately resulting in apoptosis, they do not account for
the overwhelming majority of sALS cases in which no genetic
inheritance has been found. A limited ability of MNs to balance
intracellular Ca2+ levels, however, may very well be attributable
to sALS cases as well. Given the large cytoarchitecture of MN
axons this raises the question whether mitochondrial phenotypes
in ALS could be a matter of inert susceptibility being an
early event in the onset of MN degeneration. Other than
heritable genetic mutations of fALS cases, factors interfering
with mitochondrial function and Ca2+ homeostasis, such as
environmental perturbagens and/or yet to be identified modifier
genes, could provoke prolonged mitochondrial stress and
affect cell function in sALS cases. Compelling evidence exists
pointing to approaches that artificial manipulation and rescue of
mitochondrial dynamics may lead to new therapeutic approaches
that would, to the least, extend MN life and improve disease
conditions in patients (Chen and Chan, 2009).
Screening and Reversing Mitochondrial
Phenotypes
Amajor hurdle in clinical progression of ALS still is that the time
for a definite diagnosis of patients, which may take 15 months
or longer. Given an average life expectancy of 3–5 years, it is
crucial to develop faster means of clinically detecting ALS. As a
complex disease with a wide range of phenotypical presentation,
in the clinic as well as in animal models, mitochondrial stress and
dysfunction represent a common feature of MN degeneration
(Talbot, 2014) and may proof valuable as molecular markers
in future diagnostics. Rescuing mitochondrial dysfunction in
ALS ultimately represents a valuable target for many other
neurodegenerative diseases as well. Human stem cell derived
disease-in-a-dish models could provide additional insight.
Patient-derived fALS iPSCs have been shown to reproduce some
of the neuronal stress and degeneration phenotypes (Donnelly
et al., 2013; Sareen et al., 2013; Kiskinis et al., 2014;Wainger et al.,
2014). In vitro screening in humanMNs and reversing associated
mitochondrial dysfunction signatures may thus represent an
invaluable means of unraveling molecular signatures of human
neurons.
ENDOPLASMIC RETICULUM (ER) STRESS
The ER is the primary compartment in which secreted and
membrane proteins are processed to ensure proper folding via
different classes of folding mediators. A cohort of molecular
chaperones assists the folding process of unfolded or misfolded
proteins preventing aggregation. Such chaperones are found
in multiple sub-cellular compartments, and each of those
compartments possesses its own subset of chaperones (Zapun
et al., 1999). A number of stress conditions can interfere with the
normal function of the ER leading to abnormal oxidative folding
of proteins at the ER lumen inducing ER stress (Boillée et al.,
2006a; Pasinelli and Brown, 2006; Matus et al., 2013). Mutations
in ALS disease causative genes, such as TARDBP/TDP-43,
FUS/TLS, and vesicle-associated membrane protein-associated
protein B (VAP-B), for instance, trigger aggregation of the
mutant proteins leading to a gain of neurotoxic activity and
provoking ER stress (Andersen and Al-Chalabi, 2011; Turner
et al., 2013). These conditions engage the UPR, a signal
transduction pathway responding with increased protein folding
capacity and quality control mechanisms of the ER to restore
homeostasis (Hetz et al., 2011; Walter and Ron, 2011). Chronic
ER stress, however, yields irreversible damage of the neuronal
cells and ultimately MN death (Hetz, 2012).
Three major stress sensors activate the UPR. (1) The
inositol-requiring transmembrane kinase/endonuclease (IREI1),
the PKR-like ER kinase (PERK), and activating transcription
factor 6 (ATF6). IREI1 initiates splicing of an mRNA coding
for the transcription factor X-Box-Binding protein 1 (XBP1),
converting it into a potent activator of multiple UPR-
responsive genes, the XBP1s (Calfon et al., 2002). XBP1s in
turn control the expression of genes responsible for protein
folding, protein quality control, and secretion or ER-associated
degradation (ERAD; Acosta-Alvear et al., 2007), while IREI1
further engages in degradation of specific subsets of RNAs and
pathways involving Janus Kinases (JNK), mediating apoptosis
and autophagy levels (Ron and Walter, 2007). (2) PERK is a
stress sensor and once activated, reduces protein translation
into the ER by phosphorylation of the eukaryotic initiation
factor 2 alpha (eI2Fα), leading to a decrease in misfolded
protein overload (Harding et al., 1999). The eI2Fα enables
expression of the gene ATF4, which in turn upregulates a
cascade of UPR-targeted genes responsible for amino acid and
redox metabolism, protein folding, autophagy, and apoptosis.
One of those target genes, CHOP, is a crucial mediator of
apoptotic processes in response to ER stress, supposedly via
driving the expression of pro-apoptotic Bcl-2 family members,
such as BIM and PUMA (Tabas and Ron, 2011; Walter
and Ron, 2011), in addition to GADD45. Sustained PERK
activation, however, contributes to apoptosis by increasing
oxidative stress and resuming protein synthesis after prolonged
ER stress (Marciniak et al., 2004; Verfaillie et al., 2012; Han
et al., 2013). (3) The third major stress sensor, ATF6, is
activated in the ER and translocates to the Golgi apparatus.
Following processing, its released cytoplasmic domain acts as
a transcription factor (Walter and Ron, 2011). The activated
ATF6 in turn controls certain sets of target genes related to
protein folding and quality control (Haze et al., 1999; Chen et al.,
2002).
Misfolded Proteins and Protein Aggregates
in Motoneuron Disease
Familial ALS mutations have been associated with an
accumulation of misfolded proteins (Andersen and Al-Chalabi,
2011; Turner et al., 2013), increased ER stress and dysfunction as
well as pathogenic structural alterations of the ER in ALS patient
tissue (Oyanagi et al., 2008; Sasaki, 2010; Vijayalakshmi et al.,
2011). In human postmortem tissue of sALS cases ER stress was
evident by distended and fragmented ER cisternae in affected
cells of the anterior horn of the spinal cord. Ribosome-free
membranous structures extending from the ER and electron
dense material resembling Bunina bodies, Hirano bodies and
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honeycomb-like structures were observed in samples as well
(Oyanagi et al., 2008; Sasaki, 2010; Vijayalakshmi et al., 2011).
Interestingly, a recent study immunolabeling patient tissue with
GRP78 for BiP expression found even normal appearing MNs
labeled and display dilated ER lumen with amorphous and
granular material in electron microscopy analysis (Oyanagi et al.,
2008). However, many technical limitations exist in interpreting
causative processes and the precise kinetics in many cellular
neuropathological observations made in post-mortem ALS
tissue.
TDP-43, a member of the heterogeneous nuclear
ribonuclearprotein (hnRNP) subclass of 2xRBD-Gly proteins,
shuttles between the nuclear and cytoplasmic compartments,
binding both DNA and RNA, and is involved in exon splicing of
several genes (Chen-Plotkin et al., 2010). In both ALS and FTLD
pathogenesis TDP-43 was found as themost frequent component
of ubiquitinated protein inclusions. The clinical histopathology
is characterized by cytoplasmic inclusions of skein-like or dense
granular appearance and by clearance of TDP-43 from the
nucleus (Geser et al., 2008). TDP-43 can bind to RNA in a single-
stranded and sequence-specific manner, required for many
RNA processes, and its most C-terminal portion bears unique
characteristics making it prone to misfolding and aggregation
(Buratti and Baralle, 2008; Johnson et al., 2009; Achsel et al.,
2013; Al-Chalabi and Hardiman, 2013).
Expansions of a hexanucleotide G4C2 repeat in the first
intron/promoter region of the C9ORF72 gene were identified
as the most frequent genetic cause of both f/sALS cases and
FTLD (Dejesus-Hernandez et al., 2011; Renton et al., 2011;
Gijselinck et al., 2012). Reports suggested that the repeat is
transcribed and leads to accumulation of repeat-containing
RNA foci in patient’s tissues (Dejesus-Hernandez et al., 2011).
Studies using stem cell models of ALS, one by the Sattler and
Rothstein groups and another by our group (Donnelly et al.,
2013; Sareen et al., 2013), generated iPS cells from patients
with ALS caused by C9ORF72-associated repeat expansion.
While patient-iPSC derived MNs were not adversely sensitive to
cell death processes, they exhibited certain electrophysiological
phenotypes. The mutant C9ORF72 transcript containing G4C2
repeat expansions conferred a gain of function neurotoxicity,
which was abolished upon correcting gene expression profiles
by anti-sense oligonucleotides (ASOs) introduction (Donnelly
et al., 2013; Sareen et al., 2013). C9ORF72 mutant animal
models, with one exception (Koppers et al., 2015), reported
to recapitulate key molecular signatures unique to the intronic
G4C2 repeat expansion, including RNA-foci and inclusions of
dipeptide repeat (DPR) expansion inclusions, TDP-43 pathology,
and behavioral abnormalities similar to symptoms observed
in C9ORF72/ALS patients (Chew et al., 2015). Furthermore,
some of these studies were able to associate C9ORF72 repeat
expansions to interfere with nucleocytoplasmic shuttling and
identified elements of the nuclear import/export machinery to
either enhance or suppress DPR mediated toxicity in Yeast and
fly models (Freibaum et al., 2015; Jovicic et al., 2015; Zhang et al.,
2015).
Many fALS mutation occur in genes encoding key
components of protein quality control. This includes
components essential for the retrograde transport of
autophagosomes from axons to the cell body such as dynein
and dynactin (Moughamian and Holzbaur, 2012; Ikenaka et al.,
2013), the autophagic adaptor p62 (Fecto et al., 2011), as well
as the UBA-containing proteins Ubqln2 and Optineurin (Fecto
and Siddique, 2012). Elevated levels of ER chaperones, foldases,
cell death signals and upregulation and activation of the IREI1,
PERK and ATF6 branches of UPR signaling have been reported
by multiple studies in sALS patient spinal cord tissue (Ilieva
et al., 2007; Hetz et al., 2009; Ito et al., 2009). Misfolded proteins
are constantly generated in many compartments of the cells, and
are usually removed by quality control systems composed of the
ubiquitin (Ub)-proteasome system (UPS), chaperone mediated
autophagy (CMA) andmacroautophagy. Proteins that escape the
surveillance of the UPS and CMA or tend to form aggregates are
subjected to macroautophagy for degradation into amino acids
(Hariharan et al., 2011; Koga and Cuervo, 2011; Ciechanover
and Kwon, 2015). SOD1 and TDP-43 may additionally perturb
their folding, leading to the formation of β-sheet enriched
aggregates (Andersen and Al-Chalabi, 2011) that are resistant
to all known proteolytic pathways and can further grow into
inclusion bodies and extracellular plaques (Figure 2; Koga and
Cuervo, 2011).
Aggregating proteins form intracellular inclusions containing
Ub and Ub ligases, as found in animal models (Bruijn et al.,
1997; Bendotti et al., 2004) and patient tissue (Leigh et al.,
1991; Bendotti et al., 2004; Sasaki, 2010) becoming visible in
the brain stem and spinal cord at onset of the manifestation
of ALS symptoms (Watanabe et al., 2001). Although these
large inclusions are clinical hallmarks of ALS symptoms, they
are unlikely to be toxic to neurons. In fact they may be a
neuroprotective phenomenon, as monomeric and oligomeric
misfolded ALS proteins seem to be toxic to MNs (Guo et al.,
2010). Monomeric and oligomeric misfolded proteins in turns
may exert the actual toxicity in ALS according to recent
findings suggesting a ‘‘prion-like’’ focal propagation of the
disease (Polymenidou and Cleveland, 2011; Sugaya and Nakano,
2014). In support of that mutant and wild-type SOD1 have
been found to spontaneously fibrillize (Grad et al., 2011; Munch
et al., 2011) and both TDP-43 and FUS were proposed to
contain a prion-like glutamine/asparagine (Q/N)-rich domain
found in inclusions. In vitro these inclusions exhibited ordered,
self-perpetuating aggregation and were transmissible from one
cell to its progeny (Ito et al., 2011; Polymenidou and Cleveland,
2011).
Despite an ever growing number of ALS-causative genes
having been identified, yet, difficult to identify one key factor
driving disease progression in MNs. Protein misfolding and
the effects of mono- and oligomeric forms on sequestering
functional RNAs and proteins from cellular processes constitute
a plausible cause of MND and are in alignment with
many of the ALS typical hallmarks found in ALS post
mortem tissue. Given the sensitivity of RNA and protein
metabolism, rapid development of disease phenotypes (i.e.,
TDP43, C9orf72) are often observed in animal models such
as mice and flies. The corresponding genetic mutations in
ALS patients however, display later in life with median onset
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age greater than 50. Many more elements of ER stress
responses, i.e., the UPR, have been found to impact phenotypes
of animal models and reviewed elsewhere (Matus et al.,
2013).
Screening Assays for Testing and
Reversing UPR Phenotypes
A number of studies have shown that ER chaperones can be
secreted into the extracellular space upon cellular stress (Dorner
et al., 1990). In line with this is the finding of PDIA1 levels being
upregulated in the cerebrospinal fluid (CSF) of ALS patients
(Atkin et al., 2008) and a study exposing spinal MNs to CSF of
ALS patients documented an induction of ER stress in the MNs
(Vijayalakshmi et al., 2011). Furthermore proteomic biomarkers
in blood samples of ALS patients revealed the up-regulation of
chaperones, such as the ER-stress responsive chaperones PDIA1
and ERp57. This was also confirmed for mononuclear cells from
blood of mSOD1 mouse models. Finally, in a longitudinal study
TDP-43, cyclophillin A, and ERp57 were strongly associated with
disease course in ALS patients and control subjects (Nardo et al.,
2011).
UPR signaling responses convert information about the
nature and intensity of the occurring stress into a network of
partially overlapping target genes that orchestrate an adaption
to the stress, or trigger cell death programs as a last resort.
Given the need for biomarkers to quantitatively assess disease
stage, prognosis and efficacy of clinical trials, these studies
suggest measuring stress factors released into the CSF or
the blood as a valuable tool for diagnosis and monitoring
ALS disease progression. Regardless of the origin of cellular
stress in MNs, it is increasingly clear that modulating stress
due to protein (mis-)folding and the proteostatic capacity of
MNs represent a promising therapeutic target to delay the
symptomatic phase of ALS. With regard to this, utilizing gene
therapy or small molecule approaches to reinforce the capacity
of coping with ER stress mechanisms may be an applicable
means for disease intervention (Matus et al., 2013). While animal
models of ALS provide valuable insight into many aspects of
genetically linked disease progression in vivo, there are, however,
limitations to these mouse models with regard to specificity
of the human disease phenotypes (Table 3). To this end, ALS
patient-derived iPSCs and fluorescent reporter cell lines can
serve as an important complementary tool to monitor and
TABLE 3 | Hallmarks of ALS in animal models.
Clinical ALS Animal models of ALS
phenotypes SOD1 Wobbler FUS TDP-43 ALS2 P150glue C9ORF72
Macroscopic hallmarks (M) ± (M) + M (+) (M) ± M (−) (M) ± (M) +
Degeneration of upper and lower MNs + +LMN + +LMN − + +
+ MN +LMN MN +
± MN +
±
Vesicle traffic defects + + + + ND + +
ND
Enlarged endosomes vacuolization + + + + ND + +
±
Impaired axonal transport + + + + + +
+
Protein mis-sorting G93A + ND +
Ubiquitin-positive protein aggregates G93A + + + ND ND +
± ± ±
TDP-43-positive protein aggregates (−) + + ± ND ND +
± ± ±
Neurofilament aggregations (perinuclear) G93A + ND ND ND ND
Res ± ±
Mitochondrial alteration G93A + ND + ND ND
ND
Cortical + + + ND + ND
hyperexcitability/excitotoxicity ND ND
Astrogliosis + + + + − + +
Microgliosis + + + − + +
NMJ and Muscle atrophy + + + ± ± + +
+ +
± ND +
±
Hyperexcitability, reduced GABAergic inhibition G93A + + +
ND
Cellular and molecular features presenting in clinical ALS are listed in the far left column. Some of the most frequently found mutations found associated with fALS and
sALS are represented at the top and the phenotypes found in animal models summarized for each category. Color coding: Black, mouse/rat; Red, fruit-fly; Green, worm;
Blue, zebrafish; +, phenotype; −, no phenotype; ±, variable phenotype among different animal lines; Res, restricted phenotype; ND, not determined (yet).
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discover molecular markers of ER stress and UPR, specifically
in different subclasses of MNs from patients bearing the patient
genotype.
HUMAN STEM CELL DISEASE MODELS
FOR ALS
The majority of disease processes involve multiple cell and
tissue types and in principle, are best modeled utilizing animals.
Not surprisingly, animal models have been instrumental to
our understanding of human disease pathology, including
neurodegenerative diseases such as PD, AD and ALS.
Nonetheless, many neurodegenerative diseases, such as those
affecting MNs, in fact do not naturally occur in commonly used
laboratory animals. Introduction of certain pathogenic aspects
of human neurodegenerative diseases with mutant genes being
wildly overexpressed into animals often creates phenotypes that
only partially resemble the original human disease (Table 2).
Introduction of mSOD1 into mice to induce disease
phenotypes that resemble those manifested in patients requires
expression of multiple copies of mSOD1. In human patients, a
single copy is sufficient (Bruijn et al., 1997). Moreover, the most
prevalent form of mSOD1 in ALS patients, the alanine to valine
substitution (A4V), does not appear to generate phenotypes in
mice (Furukawa et al., 2006). Thus, differences do exist between
humans and mice, with the pathogenic potential of mSOD1
just being one example, that may complicate the study of some
mutations in animal models alone. Astrocytes have also been
found to be very different between humans and rodents and
could add a potential caveat in disease modeling (Oberheim et al.,
2009). However, as illustrated in the previous chapter, glial cells
such as astrocytes have a critical role in the pathogenesis of
ALS and other neurodegenerative diseases. As a consequence, the
utilization of model systems with a human background as means
of complementing studies in animal models can greatly benefit
our understanding of MNDs.
hESCs and iPSCs as Disease-In-A-Dish
Models
In order to establish human disease models, there are
two main routes of approach. The first approach is to
genetically alter human stem cells with the target gene(s)
of interest, and the second is to derive stem cells from
patients with target diseases. The genetic modification of mouse
embryonic stem cells (ESCs) by targeting specific gene loci
via homologous recombination has been routinely applied in
many laboratories as a first step to creating transgenic animals.
Likewise, this same principle is applicable when using human
embryonic stem cells (hESCs; Zwaka and Thomson, 2003).
Repeated cellular cloning, however, as is required by traditional
approaches using homologous recombination, can often render
the established hESC cell line unstable. Alternatively, random
gene insertion, by lenti-viruses for instance, can reduce
cloning cycles significantly, yet transgenes that are integrated
during the stem cell stage may be downregulated during
differentiation (Xia et al., 2007). When Du et al. (2009)
screened for gene loci resistant to gene silencing using a
lentiviral vector with built-in Cre-loxP cassette, they were able
to establish cell lines that were resistant to gene silencing
even upon differentiation of these hESCs into neurons and
astrocytes. These master cell lines in turn allow for the
introduction of any gene of interest, including genes provoking
human diseases, via the built-in Cre-loxP cassette through
Cre recombination with high efficiency. In addition, recent
technological advances allowed for the use of zinc fingers to
target specific gene loci with high efficiency (Hockemeyer et al.,
2009), alleviating the necessity to screen large numbers of cell
clones.
The second approach, obtaining human stem cells with
disease traits capturing the patient genotype, has been made
available ever since the hallmark discovery that human induced
pluripotent stem cells (hiPSCs) can be generated from somatic
cells such as fibroblasts (Takahashi et al., 2007; Yu et al., 2007;
Hanna et al., 2010). Somatic cells can be transitioned into
iPSCs exhibiting phenotypes very similar to hESCs by expressing
pluripotency factors such as Oct3/4 and Sox2 combined with
either Klf4 and c-Myc, or Lin28 and Nanog (Takahashi et al.,
2007; Yu et al., 2007). With similar approaches hiPSCs were
generated from somatic cells harvested from patients withMNDs
including ALS (Dimos et al., 2008;Table 4) and SMA (Ebert et al.,
2009; Sareen et al., 2012). These hiPSCs can be differentiated can
be readily differentiated into neurons and astrocytes.
Many of the disease phenotypes such as MN death, or
glial cell impairment occur in iPSC derived differentiated cells
(Table 5), emphasizing that patient hiPSCs may provide a
versatile model to dissect the cellular and molecular mechanisms
underlying MN degeneration (Table 4). A recent study by
Zhang and colleagues utilizing patient derived mSOD1 iPSCs
(D90A and A4V) as a model for MN degeneration in ALS
found mutant SOD1 to exhibit neurofilament aggregation
specifically in MNs (Chen et al., 2014). This was accompanied
by decreased stability of NF-L mRNA and binding of its
3′UTR by mSOD1, yielding altered protein proportion in
NF subunits. Expression of a single copy of mSOD1 could
mimic this MN-selective phenotype in hESCs as well, while
a genetic correction of mSOD1 in patient-derived iPSC MNs
could revert the phenotype. Interestingly, conditional NF-L
expression in the mSOD1 iPSC derived MNs corrected the
NF-subunit proportion, mitigating NF aggregation and neurite
degeneration in MNs. This suggests an mSOD1 mediated
misregulation and aggregation of NF heavily impacts axonal
degeneration in ALS MNs (Chen et al., 2014). Moreover,
two other studies using patient derived mSOD1 iPSC models
reported transcriptional and functional changes inmitochondrial
and ER stress pathways as causes of perturbed electrochemical
activity in ALS neurons (Kiskinis et al., 2014; Wainger et al.,
2014).
Noteworthy, the studies above were also able to analyze
patient iPSC-derived MNs harboring repeat expansions in
C9ORF72 and retrieve a subset of the transcriptional changes
found in the mSOD1 iPSCs, indicating these are being broadly
conserved in ALS (Kiskinis et al., 2014; Wainger et al.,
2014). Other studies revealed disease specific phenotypes,
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TABLE 4 | Human stem cell models of ALS.
Human stem cell models
Mendelian fALS SOD1 hiPSCs—Strong ALS-like phenotypes in MNs, including neurite and axonal
degeneration, protein aggregation and mitochondrial alterations, some TDP-43
abnormalities observed (Yang et al., 2013; Kiskinis et al., 2014; Chen et al., 2014)
FUS hiPSCs—Mutant FUS-P525L forms cytoplasmic aggregates in MNs (Wainger
et al., 2014; Liu et al., 2015)
TDP-43 hiPSCs—ALS MND phenotype variations, excessive MN death vs. enhanced
vulnerability and dendrite alterations; TDP-43 proteinopathy and cytoplasmic
aggregates, astrogliosis (Bilican et al., 2012; Egawa et al., 2012; Serio et al.,
2013; Tsao et al., 2012)
Genetic abnormality in fALS and sALS C9ORF72 hiPSCs—Increased MN susceptibility; presence of abnormal RNA foci and
accumulation of non-ATG-dependent translation, TDP-43 pathology (Zhang
et al., 2015; Sareen et al., 2013)
An overview of human stem cell models utilized to study the cellular pathology of MND in vitro. The left column Mendelian and atypical forms of ALS associated mutations.
In the middle columns representative model terminology and disease associated genes are listed and the right column summarizes in how far ALS associated phenotypes
are resembled in the designated models.
TABLE 5 | Phenotypes of human stem cell models of ALS.
Clinical ALS phenotypes Human stem cell models of ALS
SOD1 FUS TDP-43 C9ORF72
Macroscopic hallmarks + + ± +
Degeneration of upper and lower MNs + + ± +
Vesicle traffic defects ND ND ND ND
Enlarged endosomes vacuolization + ND ND ND
Impaired axonal transport ND ND ND ND
Protein mis-sorting + ND ND +
Ubiquitin-positive protein aggregates + + + +
TDP-43-positive protein aggregates ND ND + +
Neurofilament aggregations (perinuclear) + ND + +
Mitochondrial alteration + ND ND +
Cortical hyperexcitability/excitotoxicity ND + ND ND
Astrogliosis ND ND + +
Microgliosis ND ND ND ND
NMJ and muscle atrophy Neurite and ND Neurite and Neurite and
axonal degeneration ND axonal degeneration axonal degeneration
Hyperexcitability, reduced GABAergic inhibition + + + +
Cellular and molecular features presenting in clinical ALS are listed in the far left column. Some of the most frequently found mutations found associated with fALS and
sALS are represented at the top and the phenotypes found in iPSCs summarized for each category. +, phenotype; −, no phenotype; ±, variable phenotype; ND, Not
determined (yet).
i.e., dysregulated gene expression, G4C2 RNA foci, and
susceptibility to excitotoxicity via a gain of function RNA
toxicity (Donnelly et al., 2013; Sareen et al., 2013). These
phenotypes could be mitigated with antisense oligonucleotides
(ASO) targeting the C9ORF72 transcript or repeat expansions
despite the presence of repeat-associated non-ATG (RAN)
translation products (Donnelly et al., 2013). RAN translation
can express homopolymeric expansion proteins in all three
reading frames, without an AUG start codon. This non-
canonical type of protein translation stands in stark contrast
to the classical rules of translational initiation, is length-
and hairpin-dependent, and occurs without frameshift or
RNA-editing as a result of the C9ORF72 G4C2 repeat
expansion (Zu et al., 2011; Cleary and Ranum, 2013).
Interestingly, C9ORF72 mutant iPSC-derived MNs displayed
activation of ER stress pathways and MN death when subjected
to the ER specific stressor tunicamycin (Donnelly et al.,
2013).
TDP-43 patient iPSC-derived mutant MNs formed de novo
cytosolic aggregates similar to those observed in postmortem
tissue of ALS patients (Egawa et al., 2012; Burkhardt et al.,
2013). Not only was this observed consistently in independent
studies, but iPSC derived mutant TDP-43 MNs were also
shown to recapitulate the same degenerative phenotype as
observed in postmortem tissue of the corresponding patient
(Burkhardt et al., 2013). Moreover, the TDP-43 iPSC derived
MNs exhibited shorter neurites and increased amount of
mutant TDP-43 protein in a detergent insoluble from Egawa
et al. (2012). Recently, mutations of TDP-43 in patient iPSC-
derived MNs associated with reduced levels of micro-RNA
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FIGURE 3 | Possible causes of ALS. The most prevalent underlying reason for MN defects are genetic perturbagens, inherited or de novo mutations. Yet, the
majority of ALS cases have not been linked to any mutation, suggesting that other effectors such as the environment may play into this as well. Thus MN phenotypes
observed in ALS may arise from genetic and/or environmental perturbagens, as depicted in the top panel. Developmental anomalies may affect the structural
integrity of neuronal cytoarchitecture as conferred by structural proteins, transport proteins, transmembrane proteins or by a disruption of RNA processing. Such
defects can interfere or even prevent the formation of synapses between neurons or at the NMJ either directly within MN or indirectly by affecting neighboring glial
cells. Triggering of autoimmune responses and chronic low-level inflammation may lead to MN degeneration as well and many of those developmental defects
manifest in electrophysiological deficiencies such as a progressive decrease in voltage-activated Na+ and K+ currents correlated with a loss of functional outputs.
Mitochondrial susceptibility due to ROS-induced OS in turn yields an inert vulnerability of MNs to excitotoxicity. An increased amount of mitochondrial stress in turn
leads to mitochondrial fragmentation and ultimately cell death. Due to their large size and long neurite outgrowths, MNs are particularly sensitive to ion fluctuations,
whether due to selective permeability for Ca2+ influx or lack of messenger clearance from the synaptic cleft. The dysregulation of intracellular Ca2+ levels has severe
implications for MN function as well. Both, the ER and mitochondria function as buffers of cellular Ca2+ homeostasis. When intracellular Ca2+ levels increase, either
by influx from the extracellular space or the ER and mitochondria, this triggers OS responses, their fragmentation and eventually progression of cell death signals that
ultimately lead to loss of electrophysiological outputs. The generation of misfolded proteins and formation of aggregates, likewise affects the functional integrity of
both organelles. Initially, misfolded proteins trigger the UPR in the ER to compensate for decreased protein translation and processing efficiency. Persistence of
misfolded proteins that escape corrective degradation mechanisms cause accumulation in the cell and ultimately lead to the formation of insoluble aggregates
interfering with cellular functions such as molecular transport and trafficking.
9 (miR-9) and its precursor pre-miR-9-2, suggesting miR-9
downregulation to be a potential common event in ALS and
FTLD (Zhang et al., 2013). A recent study in turn reported
an initial hyperexcitability followed by a loss of functional
output and synaptic activity, yielding a progressive decrease
in voltage activated Na+ and K+ currents (Devlin et al.,
2015). Interestingly, this was observed in, both, mutant TDP-
43 and C9ORF72 patient-derived MNs, suggesting an early
defect in ion channel status as a common event contributing
to potential initiation of downstream degenerative pathways
in ALS.
Taken together, familial ALS patient-iPSC models
recapitulate some of the disease phenotypes also observed
in patient tissue and some of transgenic animal models.
Human iPSC disease-in-a-dish models complement other
established models to decipher the molecular pathways
involved in ALS. Also, human iPSC-based models allow
for greater versatility in screening of human ALS disease
signatures by: (a) providing accessibility of difficult-to-obtain
CNS cell types such as MNs; (b) allowing investigations on
developmental effects of any ALS-associated mutation; (c)
giving options to analyze single mutant cells; (d) supplying
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FIGURE 4 | Molecular disease signatures of MNDs. ALS Patient derived cells, i.e., skin cells or whole blood allow for the generation of iPS cells and the
subsequent differentiation into MNs via neural progenitors. Not only does iPS cell technology now allow for the large scale production of MNs but, conceptually, also
the generation of all the diverse subtypes of upper and lower MNs affected in ALS. As a disease-in-a-dish model, patient-iPSC-derived motor neuron subtypes can
aid in unraveling the molecular mechanisms involving mitochondrial and ER dysfunction, as a cause of ALS vs. being a secondary effect after disease onset. Systems
biology approaches utilizing large scale genomics, transcriptomics and proteomics will help identify novel targets of MNDs such as ALS and SMA compared to iPSC
derived MNs from control patients. For further analysis and validation of prominent gene targets, gene editing techniques creating reporter and genetic
loss-of-function cell lines can facilitate the development of disease signatures of ALS patient iPSC-derived MNs. Particularly, collaborative efforts such as i.e., the
NeuroLINCS initiative will enable the acquisition of large data sets of cellular phenotypes and drug screening assays. Building on established data from animal
models this approach may dramatically accelerate the discovery of valid new therapeutic approaches and drug targets.
glial cells for interaction studies in co-culture with neurons;
(e) allowing prospects of ALS biomarker discovery;
and (f) providing platforms for therapeutic screening
strategies.
Identification of Molecular Markers
A crucial step on the way to treatment for ALS is the
identification of an early biomarker signature. Whether
it comprises markers of neural and glial pathogenesis,
mitochondrial and ER stress signals (Cozzolino et al., 2012;
Hetz, 2012), or early signatures before actual disease onset,
such means of diagnosis could greatly facilitate determination
of disease progression and the most applicable measures of
treatment. To yield good biomarkers ALS models need to
resemble the main characteristics of the disease phenotype in
patients and allow for easy accessibility of the involved cell types.
Animal models have been most frequently employed for this,
with rodent animals such as mouse and rat being a major source,
but even invertebrate models such as flies and worms (Carri
et al., 2015).
Patient-derived iPS cells from a large cohort of well-
phenotyped patients are another promising tool as they allow
direct study of ALS patient-derived human cell types. For
instance iPSC-derived MNs and glial cells could be screened
for secreted stress molecules found in the CSF and blood
of ALS patients (Atkin et al., 2008; Nardo et al., 2011;
Vijayalakshmi et al., 2011). Likewise, in addition to animal
models, pre-clinical models could incorporate ALS patient
iPSC-derived cells in the discovery and testing of promising
therapeutics. Such approaches have been put to test using
patient iPSCs. In a chemical screen referring to the TDP-43
aggregate endpoint, a recent study identified FDA-approved
small molecule modulators such as Digoxigenin, emphasizing
the feasibility of patient-derived iPSCs-based disease modelling
for drug screening (Burkhardt et al., 2013). Microarray analysis
of iPSC-MNs from mutant TDP-43 patients, decreases in
the expression of genes encoding cytoskeletal proteins and
small increases in genes involved in RNA metabolism was
observed. When treating the MNs with anacardic acid, a
histone acetyltransferase inhibitor, they were able to rescue the
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abnormal MN phenotype (Egawa et al., 2012). Over the next
3–4 years there will be increasing accessibility of large cohorts
of patient-derived iPSCs from thousands of ALS patients as
a result of collaborative initiatives across the USA, in part
due to funds raised by the ALS Ice Bucket Challenge, such
as the TRACK/ENROLL-ALS, NeuroCollaborative, and Answer
ALS among many others. These ALS iPSC panels bear great
potential for screening and identification of robust biomarkers
signifying various stages of ALS. In addition, iPSC-derived
neurons and glia may be used to identify large sets of markers of
diverse stressors thereby enabling the creation of an ALS disease
signature.
There are significant limitations and challenges associated
with patient iPSC-derived models. Some of these include: (a)
obtaining homogenous population of neural subtypes devoid
of undifferentiated progenitors; (b) prolonged time required in
culture for maturation; and (c) fetal/young ‘‘age’’ of the different
neural subtypes. Further development of cell sorting tools,
fluorescent reporters, and better markers (surface/intracellular)
for the human cell types is imperative. Recent advancements
in genome editing and creation of CRISPR/Cas edited reporter
iPSC lines will help solve some of these technical issues. The
big question that remains and needs addressing is whether
it is required to generate completely homogenous cellular
models (neurons or glia) to mimic human ALS-in-a-dish.
The answer is going to be context and question-dependent.
Nevertheless, a motor neuron during development will not
engender synaptic maturity without the presence of astrocytes in
culture.
iPSC Derived Cell Transplantation
Approaches
Apart from using patient-derived iPSCs for identification of
diagnostic markers, they may also bear the potential for cell-
based therapies. While such approaches have been used in
neurological diseases with focal pathology, i.e., PD (Björklund
and Lindvall, 2000), replacement of affected or lost cells in
widespread areas of the CNS, as encountered in ALS will prove
to be very challenging. However, replacement of affected cells
in critical parts of the brain and spinal cord, such as respiratory
centers, on the other hand, may be life-saving.
The progression of ALS is heavily affected by interactions
between MNs and neighboring glial cells, as outlined in the
previous chapter. Thus, replacing diseased or toxic astrocytes at
an early stage could potentially rescue MNs from degeneration.
Replacement of astrocytes in support of MN health has been
successfully conducted in a rat model of ALS. The primary
astrocytes not only survived the transplant, but also contributed
to increased animal life-span with grafted astrocytes migrating a
certain distance along the spinal cord and offering support for
MNs in the transplant site and neighboring areas (Lepore et al.,
2008). Although the human spinal cord is of course substantially
larger than that of rodent animals, it is nonetheless surgically
feasible transplant cells at multiple sites. As dramatically
enriched and even pure populations of human glial progenitors
differentiated from PSCs in a chemically defined culture system
can be produced in large quantities, production of clinical grade
human astrocytes in a clean facility is also technically feasible.
Specifically, generating astrocytes from the patient’s own somatic
cells through reprogramming to iPSCs will circumvent the
issues of immune rejection in transplantation (Liu and Zhang,
2010). We have also shown feasibility of transplantation and
integration of iPSC-derived neural progenitor cells (iNPCs) cells
into the rodent spinal cord. These iNPCs could be a promising
therapeutic strategy for ALS. In the host environment, they
differentiate into astroglia and provide the possibility of replacing
lost cells, modulating the injury environment, and creating a
permissive milieu to protect and regenerate host tissue (Sareen
et al., 2014).
Replacement of diseased MNs via transplantation of iPSC
derived neuronal cells remains very challenging. Although MN
differentiation protocols from PSCs have not achieved pure
populations, recent improvements are moving this field in
the right direction (Maury et al., 2015). Clinical applications
require xenobiotic-free reagents such as replacement of animal-
derived protein growth factors with defined small molecules for
the differentiation procedure. Moreover, grafted human MNs
were found to have a rather poor survival rate. Mouse ESC
derived MNs on the other hand survive well in transplantation
paradigms involving embryonic and neonatal CNS, with their
axons innervating muscles (Yohn et al., 2008). Likewise mouse
ESC derived MNs can also survive when transplanted into adult
mice, and their axons grow to denervated muscles (Deshpande
et al., 2006). Yet, hESC-derived MNs transplanted into adult
mice fail due to low survival (Lee et al., 2007). A recent study
employing iPSC-derived neural progenitors for transplantation
into rats, however, was able to report successful grafting and a
high survival rate of transplanted cells and specification of grafted
cells to MNs in the ventral horn of recipient animals (Popescu
et al., 2013).
Despite mostly disappointing outcomes in approaches to graft
human MNs in the CNS, the fact that mouse ESC-derived
neurons, human iPSC-derived astrocytes, and recently even
human neural progenitors can be grafted successfully bears
hope for the transplantation of neurons. Strategies to achieve
this will have to improve and promote neuron survival of
either terminally differentiated neurons or committed neuronal
precursors. In addition the grafted cells need to migrate
long distances, extend neurites and axons to innervate their
appropriate target muscles and make functional connections.
‘OMICS—UTILIZING BIG DATA TO
GENERATE DISEASE SIGNATURES
With a demographically growing number of documented cases
of neurodegenerative diseases, the urgency to define the state
and behavior of various CNS cells under homeostatic and
diseased conditions is apparent. Nonetheless, our understanding
of the CNS under diseased conditions such as neurodegeneration
observed in ALS, Huntington’s disease and PD, despite dramatic
progress over the past 3 decades, still is rather limited.
Particularly with respect to ALS, while research using animal
models has brought significant insight into some of the major
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events accompanying ALS, yet, not a single significant disease
modifying therapy exists. With patient-derived iPSCs technology
enabling the generation of CNS specific cell types, new avenues
of studying disease progression and signatures in human cells can
be explored.
The Library of Integrated Network-Based Cellular Signatures
(LINCS) is a collaborative initiative with the aim to catalog
cellular processes under conditions such as cell stress and disease.
Funded by the National Institute of Health (NIH) the LINCS
centers set out to collect large data sets of cellular events in
human diseases compared to healthy control samples. Utilizing
computational tools to integrate such diverse information into
a comprehensive view of molecular disease events and the
development of new biomarkers and therapeutics (Vidovic et al.,
2014; Liu et al., 2015). That this approach is likely to reveal a
wealth of new findings is supported by a line of previous LINCS
studies in areas of cell lineage identity, genome modification and
cancer research (Duan et al., 2014; Gujral et al., 2014; Ma’ayan
and Duan, 2014; Olson et al., 2014; Fallahi-Sichani et al., 2015).
Specifically for neurodegenerative diseases the NeuroLINCS
consortium has been established and plans to combine expertise
in the fields of iPSC technology, disease modeling, whole
genome sequencing, epigenomics, transcriptomics, proteomics,
and metabolomics to integrate cell-based assays and high-
throughput single-cell analysis with statistics, bioinformatics and
computational biology. With regard to ALS this NeuroLINCS
consortium would develop signatures of diseased motor neurons
and glial cells under various ALS genotypes and baseline
conditions. Eventually, we will determine how these patient
genotypes in the diseased neurons interact with environmental
perturbagens (glutamate and tunicamycin) to elicit responses
related to mitochondrial and ER stress. Our understanding
of the molecular circumstances of disease progression could
be dramatically improved by the generation of quantitative
molecular phenotypes and cell signatures of human neurons and
glia, providing rational intervention points.
CONCLUDING REMARKS
More than a century ago, Jean-Martin Charcot first described
a disease entity of broad neurodegeneration known as ALS.
Since then multiple molecular events associated with ALS disease
progression have been identified, each of these working in
concert leading to disease onset: (1) Developmental defects
caused by genetic mutations making certain MN subtypes
susceptible to aberrant maturation during CNS development
could lead to early degeneration in adult life; (2) An
inert susceptibility of mitochondria, provoked by an inability
to balance ROS, making MNs more prone to cell stress
and degeneration; (3) Misfolded proteins and protein-RNA
aggregates triggering the ER UPR stress responses leading to
initiation of MN apoptosis; and (4) The dysregulation of Ca2+
levels observed during disease progression is a common link to
both mitochondrial and ER stress, as both organelles finely tune
Ca2+ homeostasis. Particularly, the latter one provides putative
insights into MN susceptibility through mitochondrial stress
leading to increased local Ca2+ levels and ultimately functional
alteration of ALS-critical proteins; given that Ca2+ itself is
typically found to affect ALS-associated proteins and processes.
The post-mitotic MNs, however, are not the only cell types
affected by the pathological processes and mutant genes involved
in ALS. Glial cells, in fact, are functionally impaired, as shown in
animal and stem cell models alike, and these ultimately impact
MNs as well. Animal models and multidimensional ‘‘organs-
on-a-chip’’ will be crucial when future studies are required to
dissect CNS cell-cell interactions. However, animal models alone
will not enable us to decipher the full complexity of an ALS
patient’s phenotype. Years of research with animal models have
led tomostly ineffective treatments for ALS. In this regard human
models utilizing patient iPS cell technology continue to provide a
wealth of additional insight into the relevant disease phenotype
in pathophysiologically affected human cells. The logical next
step will be to use both animal and cell models synergistically
and coordinate collaborative efforts of large consortium studies
such as the NeuroLINCS initiative. By utilizing ‘OMICS,
longitudinal imaging, big data and machine-learning approaches
on large cohort of ALS patient iPSC-derivatives harboring both
familial and sporadic forms of the disease we may be able
to discover central ALS-specific mechanistic signatures beyond
the phenotype of an individual ALS mutation, and rather also
across sporadic disease that affects almost 90% of the patients.
Such an approach promises discovery of key biomarkers and
pathways that shift subtype-specific motor neurons and glial
cells out of balance. Whether iPS cell technology can fulfil such
commitments remains to be determined.
Short-term approaches must develop early ALS biomarkers
enabling faster patient evaluation and diagnosis. Mid-term goals
are to improve MN survival and delay disease progression
significantly, either by targeting MNs directly or indirectly
via glial cells, or employing small molecules and neurotrophic
factors to interfere with ROS production, Ca2+ deregulation and
apoptotic signaling. Long-term strategies will require a detailed
understanding of early signs of ALS initiation and the ability to
repair and regenerate at least MN sets crucial for survival and
extending life span. Recent reports (Popescu et al., 2013), provide
a glimpse of hope to utilize patient-derived iPSCs for large
scale screening of new diagnostic makers, and the perspective of
regenerative cellular therapies to improve patients quality of life.
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